
Laurus Labs Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Q1 FY25 revenue was flattish at Rs. 1,195 crores, expected to pick up in H2 FY25 due to clinical phase project deliveries.
- Oncology APIs growing strongly, with Q1 sales up 120% YoY; new oncology products validated, awaiting regulatory approvals.
- ARV franchise expected to remain stable at around Rs. 2,400-2,500 crores annually.
- CDMO business anticipates healthy growth supported by late-stage NCE project deliveries scheduled in Q4 FY25.
- Commercial supplies from about 10 products ongoing; new registrations and late-stage projects indicate commercial volumes likely from FY26.
- Expansion plans (formulations, fermentation facility at Vizag, animal health, crop protection) targeting medium to long-term growth.
- Pipeline includes 62 products under review/development with significant addressable market value.
- CMO collaborations and expanded oral solid dosage manufacturing lines expected to contribute to future revenue growth.
See what Laurus Labs management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript does not mention any specific plans for new fundraising through debt or equity in the near term.
- Current net debt stands at Rs. 2,633 crores, with a target to reduce the net debt to EBITDA ratio to less than 2.5 by March 2025.
- CAPEX of around Rs. 1800 to Rs. 2000 crores is planned over the next two years, primarily funded by advances from customers for specific CMO capacity expansions and internal resources.
- The company is prioritizing investments into high-value business segments and improving working capital efficiency without indicating the need for immediate external funding.
- No explicit mention of fresh equity issuance or debt raising during this period was found in the transcript.
See what Laurus Labs management said on order book — free account, 30 seconds.
Capex plans
Yes- Capex planned for FY24 and FY25 is around Rs. 1800 to Rs. 2000 crores, mainly directed toward CDMO and finished dosage formulations (FDF) expansion.
- Additional FDF capacity expansion at Unit-2 in Vizag: increasing from 10 billion to 13 billion tablets over 18 months, driven by specific customer CMO contracts, mostly for generic products; majority of this CAPEX will be funded by customer advances.
- Rs. 200 crore investment planned into fermentation facility at Vizag, expected to be commissioned by mid-2026, focusing on GMP pharmaceutical manufacturing.
- Ongoing investment in new R&D center at Genome Valley to support expanded CDMO capabilities.
- Total historic CAPEX of Rs. 2600 crore of which around 75% is for CDMO projects, currently underutilized due to phased project execution.
- Long-term investments include Animal Health and Crop Protection Ingredients facilities, with Crop Protection qualification targeted by end FY25.
Track Laurus Labs — get its next earnings analysis in your feed
How does Laurus Labs rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Laurus Labs rank in Pharmaceuticals & Biotechnology?
Compare Laurus Labs against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Laurus Labs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem